Piper Sandler Maintains Overweight on CG Oncology, Raises Price Target to $85
CG Oncology, Inc.
CG Oncology, Inc. CGON | 0.00 |
Piper Sandler analyst Kelsey Goodwin maintains CG Oncology (NASDAQ:
CGON) with a Overweight and raises the price target from $82 to $85.